Details

Autor(en) / Beteiligte

• Lau, Emily S.
• Liu, Elizabeth
• Paniagua, Samantha M.
• Sarma, Amy A.
• Zampierollo, Giovanna
• López, Begoña
• Díez, Javier
• Wang, Thomas J.
• Ho, Jennifer E.

Titel

Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

Ist Teil von

• JACC. Basic to translational science, 2021-01, Vol.6 (1), p.12-21

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• [Display omitted] •Gal-3 is a beta-galactoside–binding lectin that regulates inflammation and fibrosis and is highly predictive of heart failure events and mortality.•In a randomized placebo-controlled trial of MCP, Gal-3 inhibition did not influence collagen markers, echocardiographic measures, or vascular function.•Baseline Gal-3 levels were higher in women compared with men.•Consistent with previous studies, higher Gal-3 levels were associated with diabetes and reduced GFR. We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation.